Key result
Ticagrelor versus clopidogrel was evaluated in elective PCI, with findings unavailable in the abstract.
Why the study?
Oral antiplatelet therapy with aspirin and an ADP receptor blocker is crucial for reducing ischemic events in stable coronary artery disease patients undergoing elective PCI, motivating a comparison of clopidogrel and ticagrelor in this setting.
Answers are grounded in this paper and cite their sources.
Compares clopidogrel and ticagrelor in stable coronary artery disease undergoing elective percutaneous coronary intervention, highlighting optimal antiplatelet therapy.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Salama et al. (2021) studied Stable coronary artery disease undergoing elective percutaneous coronary intervention. Ticagrelor vs. Clopidogrel was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: